The necessity of therapeutic protocols for PD patients with respiratory disorders has also been included in clinical trials with antipanic medication alone or in association with asthma treatment, investigating the influence of such treatment on respiratory function and daily activities. The recommended treatment approaches for the two disorders sometimes conflict, for example, exposure to body sensations for PD versus avoidance of such triggers for asthma; relaxation to ameliorate anxiety, which could produce bronchoconstriction through a parasympathetic discharge, versus β-sympathetic agonists for asthma that could trigger panic; treatment of overperception and catastrophic interpretation of body sensations for PD versus improving poor symptom sensitivity and encouraging appropriate anxiety about symptoms for asthma.